Affinia Therapeutics Inc美股招股说明书 S-1 （2022-01-04首版）（英文版）（327页）.pdf

1、S-1 1 d25792ds1.htm S-1Table of ContentsAs filed with the Securities and Exchange Commission on January 4,2022.Registration No.333-UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933Affinia Therapeutics Inc.(Exact name of r

2、egistrant as specified in its charter)Delaware 2836 83-3789975(State or other jurisdiction ofincorporation or organization)(Primary Standard IndustrialClassification Code Number)(I.R.S.EmployerIdentification No.)43 Foundry Ave,Suite 120Waltham,MA 02453617-430-7817(Address,including zip code,and tele

3、phone number,including area code,of registrants principal executive offices)Rick ModiPresident and Chief Executive OfficerAffinia Therapeutics Inc.43 Foundry Ave,Suite 120Waltham,MA 02453617-430-7817(Name,address,including zip code,and telephone number,including area code,of agent for service)Copies

4、 to:Ryan SansomDivakar GuptaCooley LLP500 Boylston StreetBoston,Massachusetts 02116(617)937-2300 Stuart CableRobert E.PuopoloSeo SalimiWilliam A.MagioncaldaGoodwin Procter LLP100 Northern AvenueBoston,Massachusetts 02210(617)570-1000Approximate date of commencement of proposed sale to the public:As

5、soon as practicable after this Registration Statement is declared effective.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,checkthe following box.If this Form is filed to register additio

6、nal securities for an offering pursuant to Rule 462(b)under the Securities Act,please check the following box and list theSecurities Act registration statement number of the earlier effective registration statement for the same offering.If this Form is a post-effective amendment filed pursuant to Ru